Sanofi Secures $1.04 Billion License for ADEL-Y01, Novel Tau-Targeting Alzheimer's Therapy
Key Insights
ADEL (search) and Sanofi signed an exclusive worldwide license agreement worth up to $1.04 billion for ADEL-Y01, a first-in-class antibody therapy targeting acetylated tau protein (search) in Alzheimer's disease (search).
ADEL-Y01 represents a breakthrough approach by selectively targeting tau protein (search) acetylated at Lysine-280 (search), inhibiting toxic tau aggregation while preserving normal tau function.
The deal includes an $80 million upfront payment with additional milestone payments and tiered royalties, as ADEL-Y01 advances through its ongoing Phase 1 clinical trial.
ADEL (search), Inc. has entered into an exclusive worldwide license agreement with Sanofi for the development and commercialization of ADEL-Y01, a potential first-in-class antibody therapy for Alzheimer's disease (search). The agreement, announced December 15, 2025, carries a total potential value of up to $1.04 billion and represents a significant milestone in the pursuit of novel treatments for neurodegenerative diseases.
Financial Structure and Terms
Under the agreement, ADEL (search) will receive a non-refundable upfront payment of $80 million and is eligible for additional payments contingent upon achieving specified development and commercial milestones. The company is also entitled to receive tiered royalties on net sales ranging up to double-digit percentages. Sanofi gains exclusive worldwide rights to develop and commercialize ADEL-Y01 and related backup compounds.
Novel Mechanism of Action
ADEL-Y01 is a humanized monoclonal antibody that selectively targets tau protein (search) acetylated at Lysine-280 (search) (acK280). This approach represents a significant departure from existing therapies that target total tau protein. The antibody specifically inhibits the aggregation and propagation of toxic tau species—a key driver of Alzheimer's pathology—while preserving the function of normal microtubule-associated tau.
This selective targeting mechanism addresses one of the critical challenges in Alzheimer's therapy development: distinguishing between pathological and physiological tau proteins to avoid disrupting normal cellular functions.
Development Progress and Clinical Status
ADEL (search) spearheaded the entire discovery and preclinical development of ADEL-Y01 using its proprietary neural disease research and development platform. Since 2020, the company has been co-developing the asset through a joint research and development agreement with Oscotec Inc (search).
Currently, ADEL-Y01 is undergoing a global Phase 1 clinical trial, marking the first-in-human study for this novel therapeutic approach. The trial is being conducted under an Investigational New Drug (IND) application approved by the U.S. FDA.
Strategic Partnership Implications
"This strategic partnership with Sanofi, a global leader in healthcare, underscores ADEL (search)'s technological strength and highlights the therapeutic promise of ADEL-Y01," said Seung-Yong Yoon, CEO of ADEL. "By combining our scientific expertise with the proven development and commercialization capabilities of Sanofi, we hope to accelerate the delivery of this disease-modifying therapy to people living with Alzheimer's around the world."
Erik Wallstroem, Global Head of Multiple Sclerosis, Neurology and Gene Therapy Development at Sanofi, emphasized the innovative nature of the approach: "ADEL (search)'s innovative approach to targeting tau acetylation offers a promising and differentiated mechanism for addressing the underlying causes of Alzheimer's disease (search). We look forward to advancing ADEL-Y01 through clinical development to provide new hope for patients living with this devastating condition."
Company Background
Founded in 2016 by Professor Seung-Yong Yoon of Asan Medical Center, University of Ulsan College of Medicine, ADEL (search), Inc. is a biotech company developing therapeutics for neurodegenerative diseases. The company leverages a proprietary platform that targets disease-relevant protein modifications and aggregation, building a robust pipeline with ADEL-Y01 as its lead asset.